AbbVie Inc (ABBV)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. AbbVie is a wholly owned subsidiary of Abbott Laboratories (Abbott). AbbVie's portfolio of products includes a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Data based on most recent fiscal year report
Market Cap144.621 Billion Shares Outstanding1.596 Billion Avg Volume9.865 Million
1-Yr BETA vs S&P TR Current Ratio1.28 Quick Ratio1.18
View SEC Filings from ABBV instead.
Q2 2019 All Institutions Hedge Funds 1
To trade ABBV now:
Filers who had this stock in their top 10: 49 5 (0.52%)
13F Filers holding this stock: 1941 151 (15.6%)
Aggregate 13F shares on 06/30/2019: 1.007 Billion 49.82 Million
Aggregate 13F shares on 03/31/2019: 1.012 Billion 40.205 Million
Percent change: -0.54% 23.92%
Funds creating new positions: 122 25
Funds Adding to an existing position: 864 58
Funds closing out their position: 111 11
Funds reducing their position: 733 51
Heat Map Ranking for 06/30/2019 14
Heat Map Ranking for 03/31/2019 18
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

 

AbbVie Inc Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Funds Holding ABBV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

118.1 Thousand total shares from 6 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO

  • Officer
  • Director
 342,770 2019-09-10 7

ROBERTS REBECCA B

4,680 2019-08-30 1

DONOGHOE NICHOLAS SVP, ENTERPRISE INNOVATION

  • Officer
 13,090 2019-08-29 4

ALPERN ROBERT J

  • Director
 162,390 2019-08-26 5

STEWART JEFFREY RYAN SVP, US COMMERCIAL OPERATIONS

  • Officer
 66,642 2019-08-16 6

GOSEBRUCH HENRY O EVP, CHIEF STRATEGY OFFICER

  • Officer
 78,039 2019-08-14 6

AUSTIN ROXANNE S

  • Director
 117,114 2019-07-31 4

LIDDY EDWARD M

  • Director
 57,601 2019-07-30 5

DURKIN BRIAN L VP, CONTROLLER

  • Officer
 8,761 2019-07-25 5

HUDSON THOMAS J SVP, R&D AND CSO

  • Officer
 12,748 2019-07-01 1

RAPP EDWARD J

  • Director
 0 2019-06-30 6

WADDELL FREDERICK H

0 2019-06-28 1

CHASE WILLIAM J EVP, FINANCE & ADMINISTRATION

  • Officer
 170,053 2019-06-26 4

SCHUMACHER LAURA J

  • Director
 5,073 2019-06-18 8

MEYER MELODY B

  • Director
 12,648 2019-05-28 1

FREYMAN THOMAS C

  • Director
 19,988 2019-05-23 0

LEONARD JOHN M.

  • Director
 8,252 2019-05-16 0

TILTON GLENN F

  • Director
 42,504 2019-05-03 1

BURNSIDE WILLIAM H.L.

  • Director
 17,548 2019-05-03 1

HART BRETT J

  • Director
 10,062 2019-05-03 1

SALEKI-GERHARDT AZITA

  • Director
 11,556 2019-05-01 3

ALBAN CARLOS VICE CHAIRMAN

  • Officer
 168,319 2019-02-28 2

RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER

  • Officer
 15,515 2019-02-28 2

SEVERINO MICHAEL VICE CHAIRMAN

  • Officer
 115,857 2019-02-28 2

MICHAEL ROBERT A. SVP, CHIEF FINANCIAL OFFICER

  • Officer
 10,913 2019-02-28 2

HURWICH THOMAS A. VP, CONTROLLER

  • Officer
 No longer subject to file 2017-02-28 0

ROBERTS ROY S

  • Director
 27,486 2015-05-08 0

LINDER GREG W VICE PRESIDENT

  • Officer
 No longer subject to file 2013-02-28 0

ABBOTT LABORATORIES

  • 10% Owner
 0 2012-12-12 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GONZALEZ RICHARD A - Director - Officer CHAIRMAN OF THE BOARD AND CEO

2019-09-10 G 15,010 d 335,155 342,770.00 direct

DONOGHOE NICHOLAS - Officer SVP, ENTERPRISE INNOVATION

2019-08-29 P 7,525 $66.19 a 13,090 13,090.00 direct

GONZALEZ RICHARD A - Director - Officer CHAIRMAN OF THE BOARD AND CEO

2019-08-28 G 3,050 d 350,165 357,780.00 direct

STEWART JEFFREY RYAN - Officer SVP, US COMMERCIAL OPERATIONS

2019-08-16 P 15,552 $64.44 a 65,304 66,642.00 direct

GOSEBRUCH HENRY O - Officer EVP, CHIEF STRATEGY OFFICER in trust

2019-08-14 G 30,000 a 30,000 78,039.00 indirect

GOSEBRUCH HENRY O - Officer EVP, CHIEF STRATEGY OFFICER

2019-08-14 G 30,000 d 45,763 78,039.00 direct

GONZALEZ RICHARD A - Director - Officer CHAIRMAN OF THE BOARD AND CEO

2019-08-02 G 15,333 d 353,215 360,830.00 direct

AUSTIN ROXANNE S - Director

2019-08-01 P 25,000 $65.66 a 117,114 117,114.00 direct

AUSTIN ROXANNE S - Director

2019-07-31 P 30,000 $66.02 a 92,114 117,114.00 direct

AUSTIN ROXANNE S - Director

2019-07-30 P 10,000 $66.35 a 62,114 62,114.00 direct

GOSEBRUCH HENRY O - Officer EVP, CHIEF STRATEGY OFFICER

2019-07-29 P 30,000 $67.28 a 75,763 78,039.00 direct

DURKIN BRIAN L - Officer VP, CONTROLLER

2019-07-25 F 613 $67.46 d 8,508 8,761.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments